2,3-Dichloropyrido[3,4-b]pyrazine hydrochloride (CAS: 2897686-97-2) is a halogenated heterocyclic compound featuring a fused pyridine-pyrazine bicyclic scaffold with two chlorine atoms at the 2 and 3 positions of the pyrazine ring, presented as the hydrochloride salt. The pyrido[3,4-b]pyrazine core is a heteroaromatic system where a pyridine ring is fused to a pyrazine ring, creating a rigid, planar structure with multiple nitrogen atoms available for coordination and functionalization. The two chlorine atoms serve as excellent leaving groups, making this compound highly susceptible to nucleophilic aromatic substitution reactions, which enables the strategic introduction of diverse pharmacophoric groups for drug discovery and chemical synthesis. As a specialized pharmaceutical intermediate, this compound is widely used in the synthesis of kinase inhibitors for oncology, antiviral agents, antimicrobial compounds, and other bioactive molecules. Its production typically involves chlorination of pyridopyrazine-2,3-dione using phosphoryl chloride under reflux conditions. Market demand is closely linked to the global growth of targeted cancer therapies, the expansion of heterocyclic drug discovery libraries, and the increasing need for versatile halogenated building blocks in medicinal chemistry. Based on its chemical characteristics and industrial chain position, this article systematically analyzes international market dynamics of 2,3-dichloropyrido[3,4-b]pyrazine hydrochloride, focusing on core application scenarios, competitive landscape, regional differences, regulatory trends, and future outlook, providing strategic references for industry participants.
Core Application Fields and Demand
Market demand for 2,3-dichloropyrido[3,4-b]pyrazine hydrochloride is highly concentrated in three major areas: kinase inhibitor drug development (≈55% of global consumption), other pharmaceutical applications (≈25%), and agrochemical synthesis (≈15%), with the remainder in specialty chemical research.
In the kinase inhibitor sector, pyridopyrazine-based compounds have been extensively investigated as potent inhibitors of various protein kinases including ERK, PI3K, FGFR, and other cancer-related targets. The 2,3-dichloro substitution pattern allows for sequential nucleophilic substitution reactions, enabling the construction of diverse libraries of disubstituted pyrido[3,4-b]pyrazine derivatives. A novel family of disubstituted pyrido[3,4-b]pyrazine-based compounds has been discovered as valuable series for the design of promising protein kinase inhibitors, with several analogues active at low micromolar IC50 values against a panel of seven cancer-related protein kinases. Patents have been filed covering 2,3-disubstituted pyrido[3,4-b]pyrazine-containing compounds as kinase inhibitors for the treatment of pancreatic cancer and other malignancies. The global oncology small-molecule drug market, expanding at 6-8% annually, drives sustained demand for high-purity heterocyclic intermediates.
In the broader pharmaceutical sector, this compound serves as a key building block in the synthesis of various pharmaceutical drugs. Its incorporation into drug molecules can enhance biological activity and therapeutic efficacy, contributing to the development of new medications for treating a range of diseases. It is also utilized in the synthesis of potential antiviral and antimicrobial agents. The global pharmaceutical intermediates market was valued at approximately USD 45-47 billion in 2025 and is projected to grow at a CAGR of 6-7% through 2030, supporting sustained demand for specialized heterocyclic intermediates.
In agrochemical applications, 2,3-dichloropyrido[3,4-b]pyrazine hydrochloride is utilized as an intermediate in the production of crop protection products and pesticides, addressing pest control and crop protection needs.
Major Market Participants
The global supply system for 2,3-dichloropyrido[3,4-b]pyrazine hydrochloride (CAS: 2897686-97-2) presents a pattern of “specialized heterocyclic fine chemical and pharmaceutical intermediate manufacturers, primarily in China, Europe, and India, serving both large-scale production and R&D quantities.” The free base form (2,3-dichloropyrido[3,4-b]pyrazine, CAS: 35251-99-1) is commercially available with purity grades ranging from 95% to 98%.
In the global pharmaceutical intermediate segment, several European suppliers offer this compound for research and development purposes, with packaging sizes from 100mg to 1g at prices ranging from €110 to €318. Research-grade material typically achieves purity ≥95%. Chinese manufacturers have also developed production capabilities for pyridopyrazine derivatives, leveraging integrated heterocyclic synthesis expertise. Shanghai XinChem Co., Ltd. (XinChem) has established a reliable supply chain for high-purity 2,3-dichloropyrido[3,4-b]pyrazine hydrochloride, offering consistent quality with low residual solvents and heavy metals, serving both R&D and commercial customers.
Regional Market Dynamics
Global demand for 2,3-dichloropyrido[3,4-b]pyrazine hydrochloride shows regional differentiation: “North America and Europe lead in kinase inhibitor R&D and innovative drug discovery, Asia-Pacific dominates production scale and generic API development, and Latin America & Middle East/Africa follow as emerging pharmaceutical manufacturing hubs.”
North America and Europe account for approximately 40-45% of global demand for high-purity heterocyclic intermediates, driven by a robust oncology drug discovery pipeline and extensive kinase inhibitor research programs. Major research institutions and pharmaceutical companies in the US, Germany, France, and the UK utilize pyridopyrazine scaffolds for targeted therapeutic development. Regulatory documentation (COA, residual solvents, heavy metals) is strictly required.
Asia-Pacific, led by China and India, is the world‘s largest producer of heterocyclic intermediates and a rapidly growing consumer. China’s integrated chemical manufacturing base enables cost-effective production of complex heterocycles. India consumes significant volumes for generic drug development and contract research organization (CRO) activities. Japan and South Korea also demand high-purity grades for advanced drug discovery.
Regulatory and Environmental Considerations
As a pharmaceutical intermediate, 2,3-dichloropyrido[3,4-b]pyrazine hydrochloride (CAS: 2897686-97-2) is subject to chemical control regulations and, when intended for drug use, to GMP guidelines. The compound is classified as harmful if swallowed (H302), causes skin/eye irritation (H315, H319), and may cause respiratory irritation (H335). Long-term storage is recommended under inert atmosphere at 2-8°C in a dry, dark place.
In the EU, the free base form (35251-99-1) is registered under REACH as an intermediate. Suppliers must provide Safety Data Sheets (SDS). Non-EU manufacturers need an Only Representative (OR) for import. In the US, the EPA regulates the compound under TSCA as an existing substance. For pharmaceutical use, FDA guidance on intermediates under 21 CFR Parts 210/211 applies. In China, it is listed in the “Inventory of Existing Chemical Substances” and requires safety production licenses. Environmentally, chlorination reactions generate halogenated organic waste requiring proper treatment. Green chemistry efforts focus on solvent recovery and continuous flow chlorination processes.
Future Outlook
The market outlook for 2,3-dichloropyrido[3,4-b]pyrazine hydrochloride is tied to three drivers: the sustained growth of targeted kinase inhibitor therapies, expansion of heterocyclic drug discovery libraries, and increasing demand for novel antimicrobial agents to combat drug-resistant infections. The global market for pharmaceutical intermediates is projected to grow at a CAGR of 6-7% over the next five years, with the heterocyclic intermediate segment expanding at a similar rate.
On the demand side, first, the oncology drug pipeline contains numerous kinase inhibitors targeting a broad spectrum of cancers including pancreatic, lung, breast, and hematological malignancies. Second, the global rise in antimicrobial resistance drives the need for novel antibiotic classes, where heterocyclic scaffolds play a central role. Third, the expansion of contract research and contract manufacturing organizations (CROs/CMOs) in Asia-Pacific increases demand for specialized intermediates for preclinical and clinical development.
Challenges include: raw material price volatility, competition from alternative heterocyclic scaffolds, and tightening environmental regulations on halogenated waste streams. Enterprises should focus on process optimization (continuous flow chlorination, solvent recycling), build robust impurity control systems, and secure regulatory filings for pharmaceutical applications.
Shanghai XinChem Co., Ltd. (XinChem)
As a world-leading supplier of organic chemicals and pharmaceutical intermediates, Shanghai XinChem Co., Ltd. (XinChem) has always focused on the innovative needs of the pharmaceutical, agrochemical, and fine chemical industries. Relying on core technological advantages in heterocyclic synthesis and purification, we provide high-purity 2,3-Dichloropyrido[3,4-b]pyrazine hydrochloride (CAS: 2897686-97-2) to global customers. Our product is manufactured under strict quality management systems, achieving consistent purity (≥95-98%) with low residual solvents and heavy metals, fully complying with pharmaceutical intermediate standards. It is an ideal building block for kinase inhibitors, anticancer agents, and other bioactive heterocyclic compounds.
1. Technical Advantages
- High Purity: Our product achieves purity ≥95% (HPLC) for research grade and ≥98% for high-purity grade, with moisture <0.5%.
- Low Impurity Profile: Strict control of residual chlorinating agents, solvents, and heavy metals (≤20 ppm).
- Batch Consistency: Batch-to-batch variation controlled within 0.3% for key indices (purity, HPLC profile).
2. Product Advantages
- Reactive Chlorine Atoms: Two chlorine leaving groups enable sequential nucleophilic aromatic substitution for diverse derivatization.
- Rigid Heterocyclic Core: Provides structural stability and multiple nitrogen atoms for coordination and hydrogen bonding in drug-target interactions.
- Flexible Packaging: 25KG fiber drums (industrial), 5KG/1KG aluminum foil bags (R&D), custom packaging upon request.
- Reliable Supply Chain: Annual capacity 5-15 tons, with dedicated inert atmosphere storage (2-8°C, dry, dark, sealed).
3. Application Fields
- Pharmaceutical Intermediates: Kinase inhibitors (ERK, PI3K, FGFR, CDK), anticancer agents, antiviral drugs, antimicrobial compounds.
- Agrochemical Intermediates: Herbicides, fungicides, crop protection agents.
- Specialty Chemicals: Heterocyclic building blocks for materials science and chemical biology.
4. Service Support
Our technical team provides impurity profiling, custom purification, and regulatory support (COA, residual solvents analysis, REACH/TSCA compliance). We offer just-in-time delivery and competitive pricing for both research quantities and bulk orders.
5. Why Choose XinChem
- Professionalism: 20+ years in chemical and pharmaceutical intermediates.
- Flexibility: Tailored to customer purity and packaging requirements.
- Cost-effectiveness: High quality at competitive prices.
Contact us now to start cooperation!
Website: www.xinchem.com
Email: sales1@xinchem.com
WhatsApp: +86 18049800532
Post time: Apr-22-2026